Condition (MeSH)
Agnosia
ClinicalTrials.gov lists 2,942 trials for Agnosia or a narrower condition beneath it. Zagazig University has the most among industry and government lead sponsors, with 26.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
2,939 of the 2,942 trials are tagged with Agnosia itself; the rest are tagged with a narrower condition beneath it.
When did Agnosia trials start? (34)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 11 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 354
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 284 |
| 2025 | 354 |
| 2024 | 269 |
| 2023 | 215 |
| 2022 | 221 |
| 2021 | 229 |
| 2020 | 155 |
| 2019 | 150 |
| 2018 | 130 |
| 2017 | 121 |
Showing 10 of 34 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 340 trials starting in 2026 and about 340 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 29 months from start to primary completion across 326 trials still running at the 2026-10-09 snapshot; registered median of 12 months across 1,804 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Agnosia trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 91 |
| Phase 1/2 | 25 |
| Phase 2 | 150 |
| Phase 2/3 | 48 |
| Phase 3 | 205 |
| Phase 4 | 433 |
| Not applicable | 1,626 |
| Observational | 364 |
How many Agnosia trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 217 |
| Recruiting | 342 |
| Enrolling by invitation | 27 |
| Active, not recruiting | 77 |
| Completed | 1,656 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Agnosia trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Zagazig University | 26 |
| Pacira Pharmaceuticals, Inc | 22 |
| Ankara Etlik City Hospital | 14 |
Which drugs are being tested for Agnosia? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| +/- Bupivacaine HCl | 130 |
| DEXMEDETOMIDINE | 66 |
| PMI-150 (intranasal ketamine) | 63 |
| FENTANYL | 61 |
| Oxycodone | 38 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| PO Morphine | 89 |
| A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.) | 80 |
| L:Lidocaine | 48 |
| Ropivacaine 2 % | 46 |
| Erector Spinae Plane Block | 39 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Agnosia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hospitalization | 206 | 1 |
| Pain | 26 | 3 |
| Bone pain | 20 | 1 |
| Hospitalizations unrelated to the study | 20 | 1 |
| Pneumonia | 20 | 7 |
Showing 5 of 10 adverse events.
Which publications cover Agnosia? (46)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The effect of offline anosognosia for hemispatial neglect on neglect rehabilitation in patients with subacute and chronic right hemispheric brain injury. A retrospective cohort study. | Neuropsychological rehabilitation | 2024 | Yes |
| Combined optokinetic stimulation and cueing-assisted reading therapy to treat hemispatial neglect: A randomized controlled crossover trial. | Annals of physical and rehabilitation medicine | 2023 | Yes |
| Spatial exploration strategy training for spatial neglect: A pilot study. | Neuropsychological rehabilitation | 2022 | Yes |
| The Merging Tracks of Anosognosia and Neglect. | European neurology | 2020 | Yes |
| Association of olfactory impairment with indexes of sarcopenia and frailty in community-dwelling older adults. | Geriatrics & gerontology international | 2019 | Yes |
Showing 5 of 46 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.